Targeting SLAMF7/CS1 in vitro inhibited cell viability of human MM cell lines co-cultured with bone-marrow stromal cells (BMSCs) in a dose-dependent fashion, overcoming the stimulatory and protective effects of microenviroment on MM growth and survival (95), implying that its efficacy occurred through an indirect mechanism. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.